SPOTLIGHT: ProStrakan float flounders

The UK's ProStrakan has cut its stock valuation for the fifth time, seeking £40 million. Last May, ProStrakan outlined plans to raise £100 million. A string of European biotechs has suspended plans to go public in recent weeks amid signs of a chilly market response. Release

Suggested Articles

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.

In our EuroBiotech roundup this week, NEC and Vaximm ink cancer vaccine pact, Compugen posts cancer data and Lunac raises cash.

Biotech venture fund ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.